H.C. Wainwright has taken the unusual step of setting a $0 price target for troubled biotech Sarepta Therapeutics ...

Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a ...

Sarepta Therapeutics (NASDAQ:SRPT) saw its stock rise in after-hours trading following the announcement of a strategic review ...

Investors in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) had a good week, as its shares rose 3.3% to close at US$87.11 following the release of its yearly results. The statutory results were mixed ...

High-rolling investors have positioned themselves bullish on Sarepta Therapeutics (NASDAQ:SRPT), and it's important for retail traders to take note. \This activity came to our attention today ...

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $106.75, a high estimate of $202.00, and a low estimate of $75.00.

Ratings for Sarepta Therapeutics (NASDAQ:SRPT) were provided by 25 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The table below provides a snapshot of ...

Sarepta Therapeutics (NASDAQ:SRPT) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below provides a concise ...

Sarepta Therapeutics (NASDAQ: SRPT) and Vertex Pharmaceuticals (NASDAQ: VRTX) have a lot in common: Both operate in the tricky biotech industry, and both seek to develop treatments primarily for ...

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $164.08, a high estimate of $185.00, and a low estimate of $128.00.